TY - JOUR
T1 - Precision Health Analytics With Predictive Analytics and Implementation Research
T2 - JACC State-of-the-Art Review
AU - Pearson, Thomas A.
AU - Califf, Robert M.
AU - Roper, Rebecca
AU - Engelgau, Michael M.
AU - Khoury, Muin J.
AU - Alcantara, Carmela
AU - Blakely, Craig
AU - Boyce, Cheryl Anne
AU - Brown, Marishka
AU - Croxton, Thomas L.
AU - Fenton, Kathleen
AU - Green Parker, Melissa C.
AU - Hamilton, Andrew
AU - Helmchen, Lorens
AU - Hsu, Lucy L.
AU - Kent, David M.
AU - Kind, Amy
AU - Kravitz, John
AU - Papanicolaou, George John
AU - Prosperi, Mattia
AU - Quinn, Matt
AU - Price, Le Shawndra N.
AU - Shireman, Paula K.
AU - Smith, Sharon M.
AU - Szczesniak, Rhonda
AU - Goff, David Calvin
AU - Mensah, George A.
N1 - Funding Information:
This work was solely supported by the National Heart, Lung, and Blood Institute. The views expressed in this paper are those of the authors and do not necessarily represent the views of their affiliated institutions or agencies, including the U.S. Department of Health and Human Services, the National Institutes of Health, the Centers for Disease Control and Prevention, the Health Resources and Services Administration, and the U.S. Census Bureau. Dr. Pearson is a member of Coordinating Board for the ARRIVE Study, a completed trial of aspirin in primary prevention; and has served as a consultant to A.G. Bayer. Dr. Califf is an employee at Verily Life Sciences and Google Health/Alphabet; is a member of the Board of Directors for Cytokinetics; has served as a consultant for Biogen, Lilly, Merck, Boehringer Ingelheim, Genentech, and AstraZeneca; and has received stock and director’s fees from Cytokinetics. Dr. Engelgau has stock in Avanos and Pfizer. Dr. Kent has previously received research grants from OptumLabs and the Patient Centered Outcomes Research Institute; has received a speaker fee from Biogen; and has served on the Advisory Board for VA Health Services’ Research and Development. Dr. Szczesniak has received funding from the Cystic Fibrosis Foundation for her service on the Patient Registry Committee, Data Safety and Monitoring Board, Clinical Research Committee, and Infection Research Committee. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/7/21
Y1 - 2020/7/21
N2 - Emerging data science techniques of predictive analytics expand the quality and quantity of complex data relevant to human health and provide opportunities for understanding and control of conditions such as heart, lung, blood, and sleep disorders. To realize these opportunities, the information sources, the data science tools that use the information, and the application of resulting analytics to health and health care issues will require implementation research methods to define benefits, harms, reach, and sustainability; and to understand related resource utilization implications to inform policymakers. This JACC State-of-the-Art Review is based on a workshop convened by the National Heart, Lung, and Blood Institute to explore predictive analytics in the context of implementation science. It highlights precision medicine and precision public health as complementary and compelling applications of predictive analytics, and addresses future research and training endeavors that might further foster the application of predictive analytics in clinical medicine and public health.
AB - Emerging data science techniques of predictive analytics expand the quality and quantity of complex data relevant to human health and provide opportunities for understanding and control of conditions such as heart, lung, blood, and sleep disorders. To realize these opportunities, the information sources, the data science tools that use the information, and the application of resulting analytics to health and health care issues will require implementation research methods to define benefits, harms, reach, and sustainability; and to understand related resource utilization implications to inform policymakers. This JACC State-of-the-Art Review is based on a workshop convened by the National Heart, Lung, and Blood Institute to explore predictive analytics in the context of implementation science. It highlights precision medicine and precision public health as complementary and compelling applications of predictive analytics, and addresses future research and training endeavors that might further foster the application of predictive analytics in clinical medicine and public health.
KW - exposome
KW - genome
KW - implementation research
KW - predictive analytics
KW - social determinants
UR - http://www.scopus.com/inward/record.url?scp=85087500774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087500774&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2020.05.043
DO - 10.1016/j.jacc.2020.05.043
M3 - Review article
C2 - 32674794
AN - SCOPUS:85087500774
VL - 76
SP - 306
EP - 320
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 3
ER -